M | N | O

Product #


Product Name

Biochem/physiol Actions

Gene Symbol (ID)

Add to Cart

SML2558 N-arachidonoylglycine ≥98% (HPLC) Arachidonylglycine (NAGly) is a metabolite of the endocannabinoid anandamide (AEA) that binds to G-protein coupled receptor 18 (GPR18). It is an endogenous inhibitor of fatty acid amide hydrolase (FAAH), and also shown to be an inhibitor of the glycine transporter GlyT2. NAGly is involved in a number of pathways associated with analgesic activity and has exhibited analgesic properties in a rat model of inflammatory pain
SML2047 BPAM344 ≥98% (HPLC) BPAM344 is a potent positive allosteric modulator (PAM) on the three KAR subunits GluK1b, GluK2a, and GluK3a. BPAM344 potentiates glutamate-evoked currents of GluK2a 21-fold, and noticeably decreases desensitization kinetics (from 5.5 to 775 ms).
D6819 N2-[[5-(Diphenylmethyl)-2-furanyl]carbonyl]-L-Arginine hydrate ≥98% (HPLC), powder N2-[[5-(Diphenylmethyl)-2-furanyl]carbonyl]-L-Arginine hydrate is a C3a receptor antagonist. The Complement component 3a receptor is a G protein-coupled receptor protein involved in the complement system.
N3289 N2-Ethyl-2′-deoxyguanosine ≥98% (HPLC), solid    
M5939 (R)-N4-Hydroxy-N1-[(S)-2-(1H-indol-3-yl)-1-methylcarbamoyl-ethyl]-2-isobutyl-succinamide >95% (HPLC) GM6001 promotes cardiovascular and hepatocellular function.
Inhibits a wide variety of matrix metalloproteases with Kis in the nanomolar range. Active in a number of animal models of diseases where matrix metalloproteases are thought to be involved.
SML1967 N6-(4-Hydroxybenzyl) adenine riboside ≥98% (HPLC) N6-(4-Hydroxybenzyl) adenine riboside (NHBA) is an orally available and brain penetrant active active ingredient of Gastrodia elata rhizomes used for the treatment of insomnia. N6-(4-Hydroxybenzyl) adenine riboside is an adenosine A2A receptor and the equilibrative nucleoside transporter 1 (ENT1) agonist. It exhibits sedative and hypnotic effects by binding to adenosine A1 and A2A receptors in mice. N6-(4-Hydroxybenzyl) adenine riboside exerted a therapeutic effect on HD transgenic mouse by decreasing protein level of polyglutamine-expanded huntingtin in the striatum.
SML1660 NA-17 ≥98% (HPLC) NA-17 is a fluorescent naphthalimide that induces accumulation of activated p53 in mitochondria and nuclei of NSCLC cells. NA-17 reorganizes the Bak–Bcl-xl complex, promotes p53 phosphorylation without altering the expression of p53, induces cell cycle arrest at the G1 phase and apoptosis. NA-17 exhibits potent anticancer activities in multiple cancer cell lines showing low toxicity to normal cell lines.
SML2539 NAB-14 ≥98% (HPLC) NAB-14 is a negative allosteric modulator (NAM) selective for GluN2C/2D-containing NMDA glutamate receptors. NAB-14 was >800-fold selective for recombinant GluN2C/GluN2D over GluN2A/GluN2B in Xenopus oocytes and exhibited an IC50 value of 580 nM at recombinant GluN1/GluN2D receptors.
SML1247   NAB2 ≥98% (HPLC) NAB2 is a cell permeable and selective modifier of α-synuclein toxicity diverse cell types and PD neurons. NAB2 restores Rsp5/Nedd4 E3 ligase-dependent endosomal and endoplasmic reticulum–to-Golgi vesicle trafficking.
N3785 Nabilone solid, ≥98% (HPLC) CB1 and CB2 cannabinoid receptor agonist.
N0912 NAEPA ≥98 (TLC), solid Selective lysophosphatidic acid-1 (LPA1) receptor agonist; LPA mimetic
N0289 Nafamostat mesylate ≥98% (HPLC) Nafamostat mesylate is a broad spectrum serine protease inhibitor, kallikrein inhibitor, and inhibits blood coagulation. It is also a possible complement inhibitor.
N7662 Nafarelin acetate salt hydrate ≥95% (HPLC), solid Nafarelin acetate salt hydrate is a gonadotrophin releasing hormone analogue and luteinizing hormone releasing hormone (LH-RH) agonist.
PZ0118 Nafoxidine hydrochloride ≥98% (HPLC) Nafoxidine is a potent estrogen receptor antagonist that exhibits anti-proliferative properties. It is a non-steroidal antiestrogen, a derivative of Tamoxifen.
N158 Naftopidil hydrochloride hydrate solid α1-Adrenoceptor antagonist; antihypertensive.
human ... ADRA1A(148), ADRA1B(147), ADRA1D(146)
N4396 Nalbuphine hydrochloride hydrate ≥98% (HPLC) Partial agonist for μ and κ opioid receptors.
human ... OPRD1(4985), OPRK1(4986), OPRM1(4988)
SML2095 Nalfurafine hydrochloride ≥98% (HPLC) Nalfurafine (TRK-820) is a selective κ-opioid (KOR) agonist with antipruritic activity.
N4382 Nalidixic acid sodium salt powder Nalidixic acid sodium salt is an inhibitor of bacterial DNA polymerase (DNA gyrase) and avian myeloblastoma virus reverse transcriptase. Inhibits nucleic acid and protein synthesis in Saccharomyces cerevisiae.
N176 Naloxonazine dihydrochloride hydrate powder, ≥95% (HPLC) Potent opioid antagonist that is selective for μ1 opioid receptors.
human ... OPRM1(4988)
N7758 Naloxone hydrochloride dihydrate ≥98% (TLC and titration), powder Competitive antagonist for μ, κ, δ, and σ opioid receptors; blocks the action of σ-agonists at opioid sites. Naloxone′s antagonistic effect last for about 45 min and thus, requires repeated dosage. It results in critical side effects such as pulmonary edema.
human ... OPRD1(4985), OPRK1(4986), OPRM1(4988), OPRS1(10280)
N165 Naloxone benzoylhydrazone solid Agonist for κ3 opioid receptors; antagonist for ORL1 and μ opioid receptors.
human ... OPRK1(4986), OPRL1(4987), OPRM1(4988)
N129 Naloxone methiodide ≥98% (HPLC), solid Naloxone methiodide has low affinity for opioid receptors than naloxone. Administration of naloxone inhibits opioid receptor and opioid-induced respiratory depression.
Quaternary salt of naloxone that, like the parent compound, is a nonselective antagonist at opioid receptors. It does not cross the blood-brain barrier.
SML1397 β-Naltrexamine dihydrochloride ≥98% (HPLC) β-Naltrexamine is a potent orally available, long lasting opioid antagonist.
β-naltrexamine is obtained from naltrexone.
N9412 6β-Naltrexol hydrate ≥96% (HPLC), powder Neutral antagonist of the μ-opioid receptor. A reduction of withdrawal effects associated with neutral μ-opioid receptor antagonists may offer advantages in treating opioid overdose and addiction.
N3136 Naltrexone hydrochloride Competitive antagonist for μ, κ, δ, and σ-opioid receptors; has greater oral efficacy and longer duration of action than naloxone.
human ... OPRD1(4985), OPRK1(4986), OPRM1(4988), OPRS1(10280)
N156 Naltriben methanesulfonate hydrate ≥98% (HPLC), solid Naltriben methanesulfonate is a highly selective δ2 opioid receptor antagonist. The relative ability of the delta antagonists benzylidenenaltrexone and naltriben to inhibit DPDPE-stimulated [35S]GTPgammaS binding suggests that the opioid receptor is of the delta-2 subtype. Ligand binding assays demonstrates biphasic binding of the antagonist to the single receptor type. [35S]GTPgammaS binding is also stimulated by [D-Ser2,Leu5,Thr6]enkepha  
N115 Naltrindole hydrochloride solid Highly selective, non-peptide δ-opioid receptor antagonist that crosses the blood-brain barrier.
human ... OPRD1(4985)
SML2090 NAMI-A ≥98% ruthenium (Ru) basis (elemental analysis) NAMI-A is a potent antimetastatic drug in vivo that is exhibits little cytotoxicity towards many cancer cell lines. Antimetastatic of NAMI-A is attributed to the formation of adducts with membrane and cytosolic proteins. Nevertheless NAMI-A induces potent and selective cytotoxic effects in several leukemia cell lines. NAMI-A exhibits low toxicity for host tissues.
SML2251 Nanchangmycin ≥98% (HPLC) Nanchangmycin is a broad spectrum polyether antibiotic recently shown to inhibit Zika virus entry. Nanchangmycin was found to potently inhibit entry in three distinct cell types including human brain microvascular endothelial cells (HBMECs) with two different strains of Zika virus. It was also found effective against other viruses such as West Nile, dengue, and chikungunya.
N5504 Naphazoline hydrochloride α-adrenoceptor agonist; imidazoline receptor agonist; vasoconstrictor.
Naphazoline hydrochloride is a sympathomimetic agent. It is also considered as a conjunctival decongestant.
human ... ADRA1A(148), ADRA1B(147), ADRA1D(146), ADRA2A(150), ADRA2B(151), ADRA2C(152)
N3631 2-Naphthoxyacetic acid sodium salt crystalline    
N193 1-Naphthylacetyl spermine trihydrochloride Blocks Ca2+ permeable AMPA receptor channels.
M1275 Naproxen sodium 98.0-102.0% Cyclooxygenase (Prostaglandin H synthase 1 and 2) inhibitor.
Naproxen binds preferably to serum albumin. The S-enantiomer of naproxen is 28-fold more potential as an anti-inflammatory drug compared to the R-isomer. The R-isomer is found to be a liver toxin and causes gastrointestinal disorders.
human ... PTGS1(5742), PTGS2(5743)
N1415 Naratriptan hydrochloride ≥98% (HPLC) Naratriptan hydrochloride is a serotonin 5-HT1B/1D receptor agonist.
human ... HTR1B(3351), HTR1D(3352)
SML2805 Narciclasine ≥98% (HPLC) New Narciclasine is a Rho/Rho kinase/LIM kinase/cofilin signaling pathway activator. Also narciclasine is an actin stress fiber formation inducer; a plant growth modulator.
Recent report in Blood Identified cinobufagin, anisomycin and narciclasine as novel expression-mimickers (Ems) that exert in vitro as well as in vivo anti-AML efficacy against AML expressing mtRUNX1. Recent report identifies cinobufagin, anisomycin and narciclasine as novel expression-mimickers (Ems) that exert in vitro as well as in vivo anti-AML efficacy against AML expressing mtRUNX1.
P0247   L-NASPA ≥98% (TLC), powder Competitive mammalian lysophosphatitic acid (LPA) receptor agonist; LPA mimetic; potent reversible antagonist of the LPA receptors expressed in Xenopus oocytes.
N3538 Nateglinide ≥98% (HPLC), solid Nateglinide is a Kir6.2/SUR1 channel inhibitor and antidiabetic. It is selective for the SUR1 subtype, which is found on pancreatic islet cells. Nateglinide evokes KATP channel-dependent insulin secretion (50-200 μM) in the absence and presence of insulin.
Nateglinide is a short-acting insulin secretagogue useful in treating type 2 diabetes. It is an insulinotropic agent effective for postprandial hyperglycemia. Nateglinide restores prandial insulin levels in a glucose-dependent manner.
human ... ABCC8(6833), KCNJ11(3767)
SML2238 NAV-2729 ≥98% (HPLC) Originally characterized as a non-nucleotide-competitive and reversible ARF6-selective inhibitor (IC50 = 1.4 μM without GEF and 2.4 μM with 100 nM ARNO or BRAG2/GEP100) that targets ARF6 GEF-binding region, NAV-2729 prevents GEF-dependent ARF1 & ARF6 activity (% inhibition of BRAG2Sec7PH-stimulated GTPase activity/[NAV-2729] = 50% Δ17Arf1/10 μM and 15% Δ13Arf6/25 μM) with higher potency against BRAG2- than ARNO-dependent ARF1 activity (64% vs. 20% Δ17Arf1 inhibition at 25 μM in the presence of respective GEF sec7 domain). NAV-2729 treatment effectively inhibits G-alpha-q downstream signaling pathways and anchorage-independent colony growth of Mel92.1 & Mel202 melanoma cells in vitro (10 μM) as well as uveal melanoma tumor establishment in Mel202 xenograft mice in vivo (30 mg/kg/day i.p.).
SML0060 NB001 ≥98% (HPLC) NB001, originally believed to be a selective inhibitor of adenylyl cyclase 1 (AC1), new evidence suggests NB001 does not interact with AC1 directly. NB001 may reduce cAMP accumulation in cells through an unknown mechanism that is dependent on AC1.
SML0812   NBD-556 ≥98% (HPLC) NBD-556 is small molecule mimetic of CD4. NBD-556 recognizes the HIV-1 envelope protein gp120 and induces restructuring of gp120 analogous to CD4 binding. The CD4-induced conformational change in gp120 is necessary for interaction with CCR5.
N5908 N-(NBD-Aminocaproyl)sphinganine ≥98%    
N6158 N-(NBD-Aminocaproyl)sphingosine β-D-galactosyl ≥98%    
N8908   N-(NBD-Aminocaproyl)sphingosine β-D-lactosyl ≥98%    
N9158 N-(NBD-Aminolauroyl)ceramide ≥98%    
N3409   N-(NBD-Aminolauroyl)sphingosine β-D-lactosyl >98%    
N3911 NBI 27914 ≥98% (HPLC) NBI 27914 is a CRF1 corticotropin-releasing factor receptor antagonist.
human ... CRHR1(1394)
N183 NBQX disodium salt hydrate ≥98% (HPLC) NBQX disodium salt hydrate is a neuroprotective AMPA/kainate glutamate receptor antagonist.
human ... GRIA1(2890), GRIA2(2891), GRIA3(2892), GRIA4(2893), GRIK1(2897), GRIK2(2898), GRIK3(2899), GRIK4(2900), GRIK5(2901)
N171 NBQX hydrate powder, ≥98% (HPLC) NBQX [2,3-dihydroxy-6-nitro-7-sulphamoyl-benzo(F)quinoxaline], an anticonvulsant provides protection against white matter damage in spinal cord crush injury and also protects oligodendrocyte in experimental autoimmune encephalomyelitis (EAE). However, its role in preventing inflammation in EAE is not yet clear.
Neuroprotective AMPA/kainate glutamate receptor antagonist.
SML2644 NCGC00135472 ≥98% (HPLC) NCGC00135472 (C2A) is a resolvin D1 (RvD1) mimetic that activates resolving D1 receptor (DRV1/GPR32) and stimulate phagocytosis of serum-treated zymosan. NCGC00135472 enhances macrophage phagocytosis of live E. coli.
SML0767   NCGC00188636 ≥98% (HPLC) NCGC00188636 (DBS) is a potent and specific inhibitor of pyruvate kinase (PYK) that binds to the enzyme active site lysine residue (Lys 335 Leishmania mexicana PYK, Lys410 HsRPYK).
N4159 NCS-382 hydrate solid, ≥98% (HPLC) γ-Hydroxybutyrate (GHB) receptor antagonist; anti­convulsant.
SML2089 NCT-501 ≥98% (HPLC) NCT-501 is a potent and selective inhibitor of Aldehyde dehydrogenase ALDH1A1, a dehydrogenase that has been found to be elevated in certain cancers and in cancer stem cells. NCT-501 had an IC50 value of 40 nM and was found to be 1000-fold selective for ALDH1A1 over other ALDH enzymes and other dehydrogenases. NCT-501 treatment of head and neck squamous-cell carcinoma (HNSCC) explants in combination with cisplatin resulted in a significant decrease in proliferating cells.
SML1659 NCT-503 ≥98% (HPLC) NCT-503 is an inhibitor of phosphoglycerate dehydrogenase (PHGDH), which catalyzes the first, rate-limiting step of glucose-derived serine synthesis. NCT-503 reduced glucose-derived serine production and suppressed the growth of both PHGDH-dependent cancer cells in culture and in xenograft tumors, and caused G1/S cell cycle arrest in MDA-MB-468 cells. NCT-503 reduced the incorporation of one-carbon units from glucose-derived and exogenous serine into nucleotides, which may contribute to its anticancer activity. NCT-503 had an IC50 value of 2.5 μM for PHGDH and was inactive against a panel of other dehydrogenases and minimal cross-reactivity in a panel of 168 G-protein-coupled receptors (GPCRs). NCT-503 was found to be noncompetitive with respect to both 3-PG and NAD+, and exhibit good stability (>98% after 48 hrs in assay buffer) and aqueous solubility.
SML1671 NCT-503 Inactive Control ≥98% (HPLC) NCT-503 Inactive Control is the inactive control probe for NCT-503, which is an inhibitor of phosphoglycerate dehydrogenase (PHGDH), the enzyme that catalyzes the first, rate-limiting step of glucose-derived serine synthesis. NCT-503 Inactive Control has an IC50 value >57 μM for PHGDH. NCT-503 has an IC50 value of 2.5 μM for PHGDH. NCT-503 Inactive Control is water soluble and has good stability, similar to NCT-503.
SML0499 NCTT-956 ≥97% (NMR) NCTT-956 is a very potent, specific inhibitor of 12-lipoxygenase (12-LO) activity, with an IC50 of 800 nM, no activity against 5-LO and greater than 25-fold selectivity over 15-LO. Specific inhibition of 12-LO by NCTT-956 in platelets blocks PKC activation, aggregation, granule secretion and αIIbB3 activation.
SML1669 NCX 4016 ≥98% (HPLC) NCX 4016 (nitroaspirin) is nitroderivative of aspirin that combines cyclooxygenase inhibitor with an NO donor. NCX 4016 improves postischemic ventricular dysfunction and to reduce myocardial infarct size in rabbit.
SML0414 NCX 4040 ≥98% (HPLC) NCX 4040 is a nitric oxide-donating form of aspirin. NCX 4040 inhibits cyclooxygenase activity and releases NO, which can down-regulate COX2 expression and reduce the levels of superoxide accumulation. In the human monocytic cell line THP1, the compound inhibits PGE2 production and cytokine expression, and appears to stabilize IkB by inhibiting proteasome function. NCX 4040 has been shown to induce apoptosis in several tumor cell lines.
SML1604 NDB ≥98% (HPLC) NDB is a selective antagonist of human Farnesoid X receptor α (FXRα) that effectively modulates FXRα down-stream genes.
SML1178 NDMC101 ≥98% (HPLC) NDMC101 (HS Cm) is a potent dipeptidyl peptidase-IV (DPPIV) inhibitor in T cells with low cytotoxicity. NDMC101 is a potent immunomodulator that inhibits production of IL-2, TNF-α and IFN-γ. NDMC101 inhibits osteoclastogenesis in experimental model of arthritis.
N5537 NDNI hydriodide solid, (The product is pure based on CHN, NMR, MS) Highly selective α4β2 nicotinic receptor antagonist
SML2278 NDT9513727 ≥98% (HPLC) NDT 9513727 is novel potent, selective and orally available C5a receptor inverse agonist.
SML0631   NE-100 ≥98% (HPLC) NE-100 is a potent and selective σ1 receptor antagonist with an IC50 value of 1.54 +/- 0.26 nM for σ1 receptors, > 55-fold selectivity over σ2 receptors and > 6000-fold selectivity over D1, D2, 5-HT1A, 5-HT2 and PCP receptors.
N1915 Nebivolol hydrochloride ≥98% (HPLC) Nebivolol hydrochloride (NEB) is used as a racemic mixture for clinical studies. It stabilizes membrane and possesses intrinsic sympathomimetic functionality. Nebivolol interaction with π-acceptors (2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ), 2,4-dinitrophenol (DNP) and 2,4,6-trinitrophenol (picric acid; PA)) is useful in the spectrophotometric detection methods.
Nebivolol is a competitive, highly selective b1-receptor antagonist with mild vasodialating properties, possibly due to an interaction with the L-arginine/ NO pathway, and is used for treatment of essential hypertension. It is 40-fold selective for β1 vs. β2, and lacks ISA (intrinsic sympathomimetic activity).
N9037 Necrostatin-1 ≥98% (HPLC) Necrostatin-1 is an inhibitor of necroptosis (non-apoptotic cell death pathway).
Necrostatin-1(Nec-1) might exhibit therapeutic benefit against patients with traumatic brain injury (TBI). In addition, it might also be used to treat other acute central nervous system (CNS) disorders that feature necroptosis as a mode of cell death. It is extensively used to study the effect of receptor-interacting protein kinase 1 (RIPK1) on cell death and inflammation in experimental disease models. Nec‐1 protects hippocampal (HT‐22) cells from glutamate‐induced oxytosis via increasing cellular glutathione (GSH) levels, decreasing reactive oxygen species production, inhibiting the nuclear translocation of apoptosis‐inducing factor and B-cell lymphoma 2 (Bcl‐2) /adenovirus E1B 19kDa‐interacting protein 3‐related pathways.
N0164 Necrostatin-5 ≥98% (HPLC), solid Necrostatin-5 is an inhibitor of necroptosis (non-apoptotic cell death pathway) by indirect inhibition of RIP1 kinase. Necroptosis is defined as alternative active cell death pathway: Death-Domain Receptor (DRs, e.g. Fas/TNFR) mediated and caspase-inhibitor insensitive with specific morphology (nuclear condensation, organelle swelling, loss of plasma membrane integrity). The necrostatins have been discovered to inhibit this pathway by inhibition of the death domain receptor-associated adaptor kinase RIP1. Three distinct mechanisms appear to be involved: T-loop dependent inhibition by necrostatin-1; partially T-loop independent inhibition by necrostatin-3 and indirect inhibition of RIP1 by necrostatin-5, since necrostatin-5 is a potent inhibitor of immunnoprecipitated RIP1, but does not inhibit recombinant RIP1.
SML2124 Ned-K ≥98% (HPLC) Ned-K is a specific and potent inhibitor of NAADP (nicotinic acid adenine dinucleotide phosphate) signaling that suppresses Ca2+ oscillations via two-pore channels (TPC1) and opening of the mitochondrial permeability transition pore (mPTP) in cardiomyocytes during simulated ischaemia and reperfusion. Ned-K protected cardiomyocytes from cell death during ischaemia and reperfusion injury in rats.
SML1101   Nedocromil sodium ≥98% (HPLC) Nedocromil is a mast cell stabilizer and anti-inflammatory and anti-allergic drug. Nedocromil inhibits the degranulation of mast cells, and prevents the activation of and mediator release from a variety of inflammatory cell types. Nedocromil inhibits release of histamine, leukotriene C4, and prostaglandin D2, but has no antihistamine, bronchodilator, or corticosteroid activity itself.
Nedocromil is considered to be more effective in treating asthma compared to a placebo.
N5536 Nefazodone hydrochloride ≥98% (HPLC), solid Novel antidepressant; mixed 5-HT2A serotonin receptor antagonist/serotonin uptake inhibitor.
human ... HTR2A(3356), HTR2C(3358), SLC6A2(6530), SLC6A4(6532)
SML0349 Neferine ≥98% (HPLC) Neferine is a bis-benzylisoquinoline alkaloid isolated from the green seed embryos Nelumbo Nucifera Gaertn (Lotus) that displays multiple pharmacological activities including anti-tumor, antidepressant-like and antiarrhythmic actions. Recent studies shown that neferine potently inhibits proliferation of human osteosarcoma cells while is low-toxic on non-neoplastic human osteoblast cells. Apparently in U2OS cells, neferine stabilizes p21 through the activation of p38 MAPK, which leads to G1 cell cycle arrest. Also, neferine inhibits Ang II-induced HUVSMC proliferation by upregulation of HO-1.
N2288 Nefiracetam solid Nefiracetam (NEF) is a pyrrolidonetype nootropic agent with various pharmacologic as well as cognition enhancing effects. In amygdala-kindled seizures, nefiracetam inhibits both electroencephalographic and behavioral seizures. NEF has a distinct anticonvulsant spectrum.
SML0909 Nefopam hydrochloride ≥98% (HPLC) Nefopam is a centrally-acting analgesic drug of the benzoxazocine chemical class. Nefopam is a non-opioid, but has a potentiating effect on morphine and other opioids. Its mechanism of action is not certain, but may involve its action as a dopamine/serotonin/norepinephrine reuptake inhibitor.
SML1736 Nelarabine ≥98% (HPLC) Nelarabine is an antineoplastic purine nucleoside analog used in T-cell acute lymphoblastic leukemia. It is a pro-drug of Ara-G, which is converted by cellular kinases to the active 5′-triphosphate, Ara-GTP. Incorporation of Ara-GTP into DNA leads to inhibition of DNA synthesis and apoptosis.
PZ0013 Nelfinavir mesylate hydrate ≥98% (HPLC) Nelfinavir is a HIV protease inhibitor; antiretroviral; and anti-tumor agent.
Nelfinavir mesylate hydrate, also known as AG1343, is used as a therapeutic agent for acquired immunodeficiency syndrome (AIDS). It acts as an antifibrotic agent and is used to treat pulmonary fibrosis in patients with systemic sclerosis (SSc). In addition, nelfinavir mesylate hydrate reduces inflammation by activating protein phosphatase 2 (PP-2) and blocking mitogen-activated protein kinases (MAPK) signaling in macrophages. It also stimulate autophagy and exhibit anti-cancer property.
N9162 Neocarzinostatin from Streptomyces carzinostaticus ≥90% (SDS-PAGE), ~0.5 mg/mL Neocarzinostatin is a protein-small molecule complex composed of an enediyne chromophore tightly bound to a 113 amino acid single chain protein. The complex possesses antiproliferative and antitumor activity. The chromophore is the active compound, which is responsible for DNA cleavage; while the apoprotein stabilizes and regulates the availability of the labile chromophore. NCS chromophore is bound non-covalently in a cleft of the binding protein and is dissociable. Upon addition of a thiol, the chromophore forms a highly reactive biradical species that can induce sequence-specific single and double strand breaks in DNA. Neocarzinostatin inhibits DNA synthesis and possesses antitumor activity in various human and animal tumors. NCS inhibits cellular proliferation by inducing G2 cell cycle arrest and apoptosis in both human papillomavirus (HPV) positive and negative cell lines.
Neocarzinostatin is a radiomimetic antibiotic substance.
SML1686 Neoseptin-3 ≥98% (HPLC) Neoseptin-3 is a highly efficacious and specific agonist of the mouse TLR4 (mTLR4)/myeloid differentiation factor 2 (MD-2) complex. Neoseptin-3 binds to MD2, changes the conformation of MD-2 and facilitates active TLR4/MD-2 dimer formation. Neoseptin-3 exhibits no structural similarity to lipid A.
Neoseptin-3 stimulates the activity of mouse TLR4 (mTLR4)/myeloid differentiation factor 2 (mTLR) independently of CD14 (cluster of differentiation 14). This activated mTLR4/ mTLR promotes canonical myeloid differentiation primary response gene 88 (MyD88) and toll-interleukin(IL) 1 receptor (TIR) domain-containing adaptor inducing interferon (IFN)-β (TRIF)-dependent signaling. In addition, neoseptin-3 also stimulates tumor necrosis factor α (TNF-α), IL-6 and IFNβ production in a dose-dependent manner.
N2001 Neostigmine bromide ≥98% (HPLC and titration), powder Neostigmine bromide is a quaternary amine. It is involved in elongating and boosting the muscarinic and nicotinic effects of acetylcholine by inhibiting cholinesterase activity. It is used in anesthesia to reverse the neuromuscular blockade produced by competitive neuromuscular blockers.
Reversible inhibitor of acetylcholinesterase that is similar to eserine, but does not cross the blood-brain barrier.
human ... ACHE(43)
N2126 Neostigmine methyl sulfate Reversible inhibitor of acetylcholinesterase that is similar to eserine, but does not cross the blood-brain barrier.
human ... ACHE(43)
SML0288 Nepafenac ≥98% (HPLC) Nepafenac is a NSAID (nonsteroidal anti inflammatory drug) that is routinely used in opthamology to control pain following cataract surgery.
Nepafenac, a prodrug of amfenac, is used in the treatment of diabetic retinopathy. It is metabolized to its active form through intraocular enzymatic hydrolysis. Nepafenac has a molecular weight of 254.28 kDa and effectively penetrates through the cornea. Its molecule structure enables nepafenac to possess better permeability. Nepafenac has a low inhibitory effect on cyclooxygenase.
human ... PTGS1(5742), PTGS2(5743)
SML0940 Nepicastat hydrochloride ≥95% (HPLC) By inhibiting dopamine β-hydroxylase (DβH), nepicastat enhances dopamine levels and norepinephrine levels in brain.
Nepicastat is a potent and selective dopamine β-hydroxylase inhibitor with an IC50 of 9 nM and negligible affinity (>10 μM) for twelve other enzymes and thirteen neurotransmitter receptors tested. Nepicastat has been shown to attenuate multiple aspects of cocaine-seeking behavior and suppress cocaine-primed reinstatement of cocaine seeking in rats, and has been in clinical trials for cocaine dependence. Nepicastat also suppressed chocolate self-administration and reinstatement of chocolate seeking in rats.
SML2576 Neramexane hydrochloride ≥95% (HPLC) Neramexane is a potent NMDA antagonist that exhibits neuroprotective effects.
N6037 Neridronate ≥97% (NMR), solid Neridronate is a bone resorption inhibitor. It is used to treat Osteogenesis Imperfecta, an "orphan disease" characterized by a fragility of the bone enough to be named the "illness of bones of crystal".
SML0550 Nestorone ≥97% (HPLC) Nestorone is a potent progesterone receptor agonist with no androgenic, estrogenic, or glucocorticoid-like activities. Nestorone has been used as a female contraceptive, and recent studies inidicate that it may be useful as a male contraceptive as well. It has also been shown to have neurogenic and neuroprotective activity.
human ... PGR(5241)
N9653 Netropsin dihydrochloride from Streptomyces netropsis, ≥98% (HPLC and TLC), powder Netropsin is an unusual n-methylpyrrole-containing oligopeptide that binds to AT-rich sequences of dsDNA, especially in the minor groove. Thus, it protects such regions from DNase I and other endonucleases, and also inhibits topoisomerases. Netropsin disrupts the cell cycle, prolonging G and arresting in G.
SML2755 Netupitant ≥98% (HPLC) Netupitant is a brain-penetrant, orally active, potent and selective neurokinin-1 (NK1) receptor (NK1R; Tachykinin receptor 1) antagonist (Ca+2 mobilization IC50 = 11.2 nM/hNK1 vs. >1 μM/rNK1 & hNK2/3; hNK1/2/3 Ki = 0.95 nM/1.6 μM/1.6 μM) that effectively blocks agonist GR73632-induced foot tapping in gerbils (ID50 = 0.5 mg/kg po 2h prior to 3 pmol/5 μL GR73632/gerbil icv). In addition to antiemetic efficacy against substance P-associated vomiting reflexes, netupitant is also reported to enhance the analgesic effects of electroacupuncture (EA) among humanized mice with sickle cell disease in response to pain in vivo (10 mg/kg/day, i.p.).
N6664 Neurodazine ≥98% (HPLC) Neurodazine is a promoter of neurogenesis. It induces a generation of new nerve cells from skeletal muscle fibers both immature, differentiated myotubes and mature skeletal muscle. Neurodazine promotes the expression of neuron-specific markers in treated C2C12 cells (neurogenesis). In addition, in conjunction with a microtubule-destabilizing agent, Neurodazine allows neurogenic conversion of both differentiated immature myotubes and mature skeletal muscle. Neurodazine is a potential alternative approach to using stem cells.
N3762 Neuromedin B ≥90% (HPLC) Neuromedin B (NMB) exhibits its effects by binding to the cell surface receptors. It facilitates its action on several contractile organs including, the stomach, intestine, esophagus, gall bladder, urinary bladder, and uterus. It also plays a role in food intake, hypothermia, and thermoregulation. NMB is involved in exocrine and endocrine secretion of gastrin, insulin, cholecystokinin, enteroglucagon, and gastric inhibitory peptide. It also acts as an autocrine growth factor in non-small cell lung cancer.
SML0354 Neuronostatin trifluoroacetate salt ≥95% (HPLC) Neuronostatin is a peptide hormone encoded by somatostatin gene that is involved in regulation of neuronal function, blood pressure, food intake and drinking behavior. Data indicates that neuronostatin regulates cardiac contractile function and cardiomyocyte survival. Also neuronostatin significantly inhibited both food and water intake when administered centrally in adult male rats.
N2412   Neuropeptide S from rat ≥98% (HPLC), powder Neuropeptide S is a novel modulator of wakefulness and anxiety.
P4488   Pancreatic Polypeptide Fragment 1-17–[Ala31, α-Aminoisobutyryl32]-Neuropeptide Y Fragment 18-36 ≥95% (HPLC), solid Selective agonist of the neuropeptide Y receptor.
human ... NPY(4852)
SML1716   Neuropeptide S human trifluoroacetate ≥95% (HPLC) Human Neuropeptide S is an endogenous agonist of human neuropeptide S receptor (NPSR) that modulates arousal, wakefulness, anxiety, fear-extinction, and fear memory consolidation.
SML0871   NeuroSensor 521 ≥98% (HPLC) NeuroSensor 521 is a fluorescent turn-on sensor designed for the selective visualization of norepinephrine over epinephrine in fixed and live cells and the fluorescence is not affected by fixation. NeuroSensor 521 binds to all primary amines, but binds catecholamines such as dopamine and norepinephrine more tightly than other biogenic amines such as glutamate and does not interact with secondary amines such as epinephrine. Because of the spectral properties of NeuroSensor 521, the unbound and bound states can be monitored using 440 and 488 nm excitation, respectively. In chromaffin cells NeuroSensor 521 stained the norepinephrine-containing cells preferentially over epinephrine-containing cells under identical conditions.
SML0097 Nevirapine Nevirapine interacts with glycine 190 residue of human immuno deficiency virus (HIV-2) reverse transcriptase. It is an antiretroviral drug which increases bile synthesis and activates electron transport chain. Use of nevirapine leads to liver toxicity and is associated with Nevirapine hypersensitivity syndrome.
Nevirapine is an allosteric, non-nucleoside inhibitor of HIV reverse transcriptase (NNRTI). The Ki for inhibition of wild-type RT by Nevirapine is 200 nM.
SML1919   Nexinhib20 ≥98% (HPLC) Nexinhib20 (neutrophil exocytosis inhibitor 20) is a potent inhibitor of the interaction between the small GTPase Rab27a and its effector JFC1 (synaptotagmin-like protein1). Nexinhib20 inhibits exocytosis of azurophilic granules in human neutrophils without affecting other important innate immune responses including phagocytosis and neutrophil extracellular trap production.
Nexinhib20 prevents the expression of cytochrome b558 in the plasma membrane. It modulates vesicular trafficking and neutrophil activities. Nexinhib20 reduces the systemic inflammation, mediated by neutrophils.
N8652 NF 023 hydrate ≥98% (HPLC), solid NF 023 is a potent, selective P2X1 purinoceptor antagonist.
human ... P2RX1(5023), P2RY1(5028), P2RY11(5032), P2RY2(5029)
SML1332 NG25 trihydrochloride ≥98% (HPLC) NG25 is potent multiple kinase inhibitor belonging to type II kinase inhibitors class that binds to kinase ATP binding pocket at not ready to catalyze conformation. NG25 is used as a potent dual inhibitor of TAK1 (TGFβ-Activated Kinase 1, MAP3K7) and MAP4K2 (Mitogen-Activated Protein Kinase Kinase Kinase Kinase 2; GCK) kinases. NG25 inhibits the activation of IKKa/IKKb and prevents the secretion of type 1 IFNs by TLR2 and TLR9 agonist.
SML0066 NGB 2904 hydrochloride ≥98% (HPLC) Inhibition of dopamine D3 receptor function by NGB 2904 increases spontaneous locomotor activity in rodents.
NGB 2904 is a potent and selective dopamine D3 receptor antagonist with a D3/D2 ratio of 800 for rat and high binding affinity (1.4 nM) at the hD3 receptor with 150-fold selectivity for primate D3 receptors over primate D2L receptors. It attenuates the rewarding effects of cocaine and methamphetamine.
SML1620   NGI-1 ≥95% (HPLC) NGI-1 (ML414) is an inhibitor of Asparagine (N)-linked glycoslysation. NGI-1 inhibits the oligosaccharyltransferase, preventing the attachment to the protein. NGI-1 has been shown to induce senescence in receptor tyrosine kinase dependent tumors.
N2162 NH125 ≥98% (HPLC), solid NH125 exhibits anti-proliferation activity against many cancer cells. It also exhibits antibacterial effects by inhibiting bacterial histidine protein kinase.
NH125 is a novel plant histidine kinase inhibitor and selective mammalian eurkaryotic elongation factor-2 kinase (eEF-2K).
SML1155   22-NHC ≥98% (HPLC) 22-NHC (22-Azacholesterol) is the first small molecule inhibitor that inhibits Hedgehog (Hh) signaling by binding the oxysterol-binding site of Smo. Oxysterols are the only known endogenous activators of Hedgehog signaling, with 20(S)-hydroxycholesterol being the most potent, and act at a site distinct from that targeted by current Smo inhibitors such as cyclopamine and SANT1. 22-Azacholesterol (22-NHC) inhibited Sonic Hedgehog (Shh) signaling with an IC50 of 3 μM in NIH-3T3 cells. 22-NHC binds to the same allosteric site as 20(S)-hydroxycholesterol (20-OHC), which is distinct from the cyclopamine site and the itraconazole site, and appears to act by competing with binding of 20-OHC to mSmo.
SML1463 NHI-2 ≥98% (HPLC) NHI-2 is an inihbitor of Lactate dehydrogenase-A (LDH-A, LDHA), a key enzyme necessary to sustain glycolysis, the major pathway used by many cancer cells for cell growth and proliferation (the Warburg effect). NHI-2 has anti-glycolytic activity against a variety of cancer cells. NHI-2 inhibited cell growth of pancreatic cancer LPC006 and PANC-1 cells and enhanced the antiproliferative effects of Gemcitabine and caused apoptosis in colon cancer HCT116 cells.
NHI-2 possesses highr cell permeability.
PZ0348 NI-42 ≥98% (HPLC) NI-42 is a biased potent small molecule inhibitor of the bromodomain of the BRPF (bromodomain and PHD finger-containing) proteins, which are scaffolding proteins that assemble histone acetyltransferase (HAT) complexes of the MYST transcriptional coactivator family. NI-42 has an IC50 value of of 7.9 nM and is suitable for cellular and in vivo studies.
SML1486 NI-57 ≥98% (HPLC) NI-57 is a selective and potent inhibitor of BRPF (Bromodomain and PHD Finger) family of proteins (BRPF1/2/3). NI-57 shows accelerated FRAP recovery at 1 μM in the BRPF2 FRAP assay preventing binding of full-length BRPF2 to chromatin. For full characterization details, please visit the NI-57 probe summary on the Structural Genomics Consortium (SGC) website.

To learn about other SGC chemical probes for epigenetic targets, visit sigma.com/sgc
SML2099 NIBR-0213 ≥98% (HPLC) NIBR-0213 is an orally active, potent and S1P1-selective sphingosine 1-phosphate (S1P) receptor antagonist that blocks S1P1-selective ligand AUY954-induced Ca2+ mobilization (IC50 = 2.5 nM using human S1P1-transfected HeLa cells; IC50 >10 μM with human S1P2, S1P3, or S1P4 transfectants) and S1P-induced GTPγS recruitment (IC50 = 2.0/2.3/8.5 nM using membrane from human/murine/rat S1P1-transfected CHO cells; IC50 >10 μM with membrane from human S1P5 transfectant). NIBR-0213 induces long-lasting peripheral blood lymphocyte reduction in rats (EDmax = 1 mg/kg, ED50 = 0.2 mg/kg; p.o.) and exhibits therapeutic efficacy (30 mg/kg p.o; BID) in experimental autoimmune encephalomyelitis (EAE), a murine model of multiple sclerosis (MS), with no adverse effects to the animals.
SML1981   NIBR189 ≥98% (HPLC) NBIR189 is a high-affinity, potent and selective EBI2 (GPR183) antagonist (IC50 = 16 nM against 10 nM 7α,25-OHC for binding human EBI2) that inhibits 7α,25-OHC-induced GTPγS binding (IC50 = 8.5 and 7.0 nM, respectively, against 0.33 and 0.1 nM OHC; human EBI2-expressing CHO membrane), calcium mobilization (IC50 = 11 and 15 nM using human or mouse EBI2-transfected cells, respectively), and chemotaxis (IC50 = 0.3 nM against 20 nM OHC-induced U937 migration). NBIR189 displays no inhibitory potency against 5HT2A, muscarinic acetylcholine receptor M2, adrenoreceptor α1A, nor significant affintiy toward 18 other GPCRs/transporters/enzymes, and exhibits good pharmacokinetic properties and oral availability in mice (AUC = 3608 nmol h/L, Cmax = 835 nM, tmax = 1 h, F = 49%; 3 mg/kg p.o.). A useful tool for probing EBI2-mediated physiological functions and autoimmune disorders.
N7510 Nicardipine hydrochloride powder, ≥98% Blocks L-type voltage-dependent calcium channels; antihypertensive.
human ... CACNA1C(775), CACNA1D(776), CACNA1F(778), CACNA1S(779)
N3539 Nicorandil ≥98% (HPLC) Nicorandil exhibits cardio-protective effects.
Nicorandil is a hybrid ATP-sensitive K+ (KATP) channel opener and nicotinamide nitrate NO donor. Nicorandil selectively activates SUR2B- versus SUR2A-containing KATP channels. It enhances endothelial NO synthase expression and protects against ischemic ventricular arrhythmias. By activating potassium channels, and donating nitric oxide to activate the enzyme guanylate cyclase, Nicorandil causes activation of GMP leading to both arterial and venous vasodilatation. Nicorandil is selective for vascular potassium channels, but has no significant action on cardiac contractility and conduction.
N3376 Nicotinamide ≥98% (HPLC), powder Nicotinamide is an amide derivative of vitamin B3 and a PARP inhibitor
human ... PARP1(142), SIRT2(22933)
72345 Nicotinamide ≥98.5% (HPLC) Nicotinamide is an amide derivative of vitamin B3 and a PARP inhibitor
Nicotinamide serves as a precursor for β-nicotinamide adenine dinucleotide (NAD+) coenzyme production. It is involved in the synthesis of NAD+ phosphate (NADP+). It also regulates the mechanism of cell survival and cell death. Fatigue, skin pigmentation, decreased appetite and mouth ulcers are indications of nicotinamide deficiency. Its chronic deficiency can lead to pellagra. Nicotinamide is known to show protective effects on oxidative stress.
N3876 (−)-Nicotine ≥99% (GC), liquid Nicotine binds to nicotinic acetylcholine receptors and exhibit both neuroprotective and neurotoxic effects on the developing brain. It is associated with lung cancer development and reduces the efficiency of chemotherapeutic agents. In addition, nicotine has an ability to impair phagocytic host defense and also increase reactive oxygen species (ROS) associated injury. It also stops Akt/ protein kinase B (PKB) deactivation and decreases spontaneous death of neutrophils. Nicotine is used to treat Alzheimer′s and Parkinson′s disease.
Prototype nicotinic acetylcholine receptor agonist; naturally occurring isomer.
human ... CHRNA2(1135), CHRNA3(1136), CHRNA4(1137), CHRNB2(1141), CHRNB4(1143), CYP2A6(1548), KCNH1(3756)
mouse ... Chrna7(11441), Chrnb1(11443)
rat ... Chrna1(79557), Chrna2(170945), Chrna4(25590), Chrna7(25302), Chrnb2(54239), Chrnb4(25103)
N1019   (−)-Nicotine hemisulfate salt ≥95% (TLC), ~35 % (w/v) in H2O (based on free base) Prototype nicotinic acetylcholine receptor agonist; naturally occurring isomer.
human ... CHRNA4(1137), CHRNB2(1141)
SML1236 (−)-Nicotine hydrogen tartrate salt ≥98% (HPLC) Nicotine hydrogen tartrate (NHT) is a biodegradable polymer of chitosan. NHT is considered to be more stable than nicotine. Nicotine is highly addictive drug and is indirectly but strongly associated with tobacco related diseases. It helps to discontinue smoking. Nicotine might serve as a therapeutic agent in treating Alzheimer’s disease, Parkinson’s disease and ulcerative colitis.
Prototype nicotinic acetylcholine receptor agonist; naturally occurring isomer.
N0267 (±)-Nicotine ≥99% (TLC), liquid (±)-Nicotine is a tertiary amine compound that is predominantly present in tobacco. It binds to the nicotinic cholinergic receptors of the brain, autonomic ganglia and neuromuscular junction. Nicotine allosterically regulates a number of biological events such as production of growth hormone, dopamine, adrenocorticotropic hormone and prolactin. Nicotine absorption across biological membranes is pH sensitive, which alters its ionization state. Absorption of nicotine is shown to be higher at alkaline pH, when it remains unionized. Nicotine metabolism occurs extensively in the liver and it can cross placenta.
Prototype nicotinic acetylcholine receptor agonist.
human ... CHRNA2(1135), CHRNA3(1136), CHRNA4(1137)
rat ... Chrna3(25101), Chrna4(25590), Chrna7(25302)
N5655 Nicotinic acid adenine dinucleotide phosphate sodium salt ≥92.5% Potent activator of intracellular Ca2+ release via an IP3 and cyclic ADP ribose-independent mechanism.
SML1156 NID-1 ≥98% (HPLC) NID-1 (Novel Inducer of Death-1) is a cell permeable and potent inducer of energy-dependent non-apoptotic cell death in mammalian cell lines. NID-1 induced cell death is distinct from macroautophagy, but still reacquires ATG5 and the lysosomal hydrolase cathepsin-L.
N8162 NIDA-41020 ≥97% (HPLC), solid NIDA-41020 is a CB1 cannabinoid receptor antagonist. NIDA-41020 is structurally similar to Rimonabant, which is currently in clinical development. NIDA-41020 is less lipophilic; developed at NIDA as a potential radioligand for CB1 receptors, Ki = 4.1 nM [in comparison AM 251, AM 281, SR 141716 (Rimonabant) have Ki of 0.6, 4.5 and 1.8 nM respectively].
N7634 Nifedipine ≥98% (HPLC), powder Nifedipine is a L-type Ca2+ channel blocker; and induces apoptosis in human glioblastoma cells. Nifedipine has neuroprotection activity and protects substantia nigra. Nifedipine has antioxidant potential. Nifedipine downregulates inflammatory cytokines like macrophage inflammatory protein-2 (MIP-2), tumor necrosis factor-α (TNF-α). Nifedipine has antihypertensive properties. Nifedipine inhibits extracellular region of adenosine A2a receptor (ADORA2A) gene.
human ... ADORA2A(135), ADORA3(140), CACNA1C(775), CACNA1D(776), CACNA1F(778), CACNA1S(779), CACNA2D1(781), CYP1A2(1544), KCNH1(3756), TTR(7276)
mouse ... Cacna1c(12288)
rat ... Adora1(29290), Adora2a(25369), Cacna1c(24239), Cacna1d(29716), Kcnj1(24521), Kcnn4(65206), Tbxas1(24886)
SML2120 Nifekalant hydrochloride ≥98% (HPLC) Nifekalant is a pure potassium channel blocker and class III antiarrhythmic. It has been used to treat arrhythmias and ventricular tachycardia.
SML1372 Nifetepimine ≥95% (HPLC) Nifetepimine is a dihydropyrimidone calcium channel blocker that down-modulates SERCA3 (sarco/endoplasmic reticulum Ca2+ -ATPase 3) pump, and protects of the CD4+ T cells from tumor-induced apoptosis. Nifetepimine induces apoptotic cell death in triple negative breast cancer (TNBC) cells by stimulation of cross-talk between ER stress and the MEK/ERK pathway.
N0630 Niflumic acid Niflumic acid (NFA), a γ-aminobutyric acid type A receptor (GABAARs) antagonist is a non-steroidal anti-inflammatory drug (NSAID) and it belongs to the fenamate class. It is also a blocker of chloride ion channel and a calcium-activated chloride channel (CaCC) inhibitor. NFA possesses anti-inflammatory property and is useful in treating rheumatic disorders. It is also an inhibitor of N-methyl-D-aspartate receptor and glycine receptor. NFA also inhibits enzymes associated with the prostaglandins synthesis.
Selective cyclooxygenase-2 (COX-2) inhibitor.
human ... PTGS1(5742)
N3415 Nifurtimox ≥98% (HPLC) Nifurtimox is a nitrofurane derivative used to treat diseases caused by trypanosomes. Nifurtimox was discovered empirically and its mechanism of action is unclear. It is believed that nifurtimox exerts its biological activity through the bioreduction of the nitro-group to a nitro-anion radical which undergoes redox-cycling with molecular oxygen.
N7143 Nigericin sodium salt ≥98% (TLC) Polyether ionophore that disrupts membrane potential and stimulates ATPase activity in mitochondria. Ion selectivity is K+> Rb+≥ Cs+>> Na+.
N8534   Nilutamide solid Nilutamide is an antiandrogen used in the treatment of prostate cancer.
human ... AR(367)
SML0945   Nilvadipine ≥98% (HPLC) Nilvadipine is a potent calcium channel blocker that is used for treatment of hypertension. Nilvadipine, as other dihydropyridine calcium antagonists, decreases intracellular calcium concentration causing dilation of the coronary and systemic arteries. Nilvadipine acutely reduced brain Aβ levels in a transgenic mouse model of Alzheimer′s disease (AD).
Nilvadipine, apart from its antihypertensive effect, is known to decrease the accumulation of β-amyloid protein in the brain. Therefore, it is effective in the treatment of Alzheimer’s disease. Nilvadipine also promotes cognitive function in hypertensive patients.
N1016 Nimesulide Highly selective cyclooxygenase-2 inhibitor.
Nimesulide can be used as a substitute to other nonsteroidal anti-inflammatory drugs (NSAIDs) to treat pain and inflammation of osteoarthritis for a short period. It can perform anti-inflammatory, analgesic and antipyretic activities.
human ... ALB(213), PTGS1(5742), PTGS2(5743)
N149 Nimodipine Nimodipine enhances the survival of dopaminergic substantia nigra neurons.
Nimodipine is a potent L-type Ca2+ channel antagonist.
human ... ADORA3(140), CACNA1C(775), CACNA1D(776), CACNA1F(778), CACNA1S(779), CACNG1(786), NR3C2(4306)
rat ... Adora1(29290), Adora2a(25369)
SML1935   Nimorazole ≥98% (HPLC) Nimorazole is a nitroimidazole-based hypoxic cell-radiation sensitizer with less toxicity than etanidazole or misonidazole. Under low oxygen (hypoxic) condition, reductive activation of its 5-nitroimidazole moiety leads to enhanced adduct formation with reduced glutathione, which form the basis of cancer/tumour-selective radiation sensitization. Nimorazole is also a known anti-infective agent against trichomoniasis, an infectious disease caused by the protozoan parasite Trichomonas vaginalis.
SML2848 Nintedanib ≥98% (HPLC) Nintedanib (BIBF1120) is an orally active, potent ATP-competitive inhibitor against angiokinases VEGFR-1/2/3 (IC50 = 34/21/13 nM), FGFR-1/2/3/4 (IC50 = 69/37/108/610 nM), PDGFRα/β (IC50 = 59/65 nM), as well as Flt-3, Lck, Lyn, and Src (IC50 = 26, 16, 195, 156 nM, repectively), but not 33 other kinases. Nintedanib exhibits antiangiogenic and antifibrotic efficacy in cultures and in animal models of cancers and pulmonary fibrosis in vivo.
UC179 (R)-(−)-Nirvanol CYP2B6 metabolite of (S)-(+)-mephenytoin; anticonvulsant; hypnotic.
UC180 (S)-(+)-Nirvanol CYP2B6 metabolite of (R)-(-)-mephenytoin; anticonvulsant; hypnotic.
UC178 (±)-Nirvanol CYP2B6 N-demethyl metabolite of (±)-mephenytoin; anticonvulsive; hypnotic
N0165 Nisoldipine ≥98% (HPLC) L-type (CaV1.2) calcium channel blocker; dihydropyridine-type calcium channel blocker with selectivity for smooth muscle (CaV1.2b) over cardiac muscle (CaV1.2a). Arterial vasodilator and antihypertensive agent.
human ... CACNA1C(775), CACNA1D(776), CACNA1F(778), CACNA1S(779)
N151 Nisoxetine hydrochloride solid, ≥98% (HPLC) Potent and selective inhibitor of the norepinephrine transporter (Ki = 5.1 nM).
N0290 Nitazoxanide ≥98% (HPLC) Nitazoxanide (NTZ) promotes autophagy by acting on kinase based signaling pathways and acts on mammalian target of rapamycin complex 1 (mTORC1) in Mycobacteria. It has anti-viral property and effectively halts entry and release of chikungunya virus in in vitro studies. NTZ also inhibits Japanese encephalitis virus (JEV) infection in early stages and has the potential to treat other viral infections including dengue, hepatitis B (HBV), coronavirus and human immunodeficiency virus (HIV). It has antineoplastic functionality and may induce apoptosis by promoting proto-oncogene c-Myc inhibition resulting in tumor suppression.
Nitazoxanide is an inhibitor of pyruvate-ferredoxin oxidoreductase (PFOR); Antimicrobial recently found to kill both non-replicating and replicating mycobacteria. FDA approved anti-parasitic drug (2002). Recent work (C & EN Sept. 14, 2009, p. 28) highlights that NTZ kills non-replicating and replicating TB bacteria and no apparent resistance is detected.
SML2409 NITD008 ≥98% (HPLC) NITD008 is a selective inhibitor of flaviviruses including dengue virus (EC50 = 0.64 μM), hepatitis C virus and Zika virus, and has also been shown to inhibit tick-borne flaviviruses in vitro. NITD008 has been reported to inhibit RNA-dependent RNA polymerase (RdRp), an essential protein of RNA viruses.
SML0671   Nitecapone ≥98% (HPLC) Nitecapone is a short-acting inhibitor of catechol-O-methyltransferase (COMT). Nitecapone displays in vivo activity in peripheral tissues, but does not pentrate the blood brain barrier. The compound increases mechanical and thermal nociception, and reduces neuropathic pain in diabetic rats and in a spinal nerve ligation model.
SML0610 Nitidine chloride ≥97% (HPLC) Nitidine chloride is a natural product with anti-cancer activity. Its mechanism of action likely involves several pathways. Nitidine chloride has been found to inhibit topoisomerase I and topoisomerase II, induce cell apoptosis by activation of the caspase-dependent pathway, suppress c-Src/FAK associated signaling pathways and suppress Janus kinase 2/STAT3 signaling and the expression of STAT3-dependent target genes, including cyclin D1, Bcl-xL, and VEGF. Nitidine chloride has also been found to have anti-malaria activity.
SML0269 Nitisinone ≥95% (HPLC) Nitisinone is a competitive inhibitor that reversibly inhibits 4-Hydroxyphenylpyruvate oxidase (dioxygenase). Nitisinone is used in the treatment of hereditary tyrosinemia type 1, where it blocks the degradation of tyrosine into harmful substances.
human ... HPD(3242)
N3889 Nitrazepam Hypnotic; ligand for the GABAA receptor benzodiazepine modulatory site.
N144 Nitrendipine >95%, powder Ca2+ channel blocker; anti-hypertensive.
human ... ADORA3(140), CACNG1(786), KCNH1(3756), TTR(7276)
rat ... Adora1(29290), Adora2a(25369)
N5501 Nω-Nitro-L-arginine ≥98% (TLC) Irreversible inhibitor of constitutive nitric oxide synthase (nNOS) and a reversible inhibitor of inducible nitric oxide synthase (iNOS).
Nω-Nitro-L-arginine/L-NNA helps to reduce the levels of cortical hyperemia and brain cGMP occurring due to hypercapnia.
human ... NOS1(4842), NOS2(4843), NOS2B(201288), NOS2C(645740), NOS3(4846)
mouse ... Nos2(18126)
rat ... Grin2a(24409), Nos1(24598)
N5751 Nω-Nitro-L-arginine methyl ester hydrochloride ≥98% (TLC), powder An analog of arginine that inhibits NO production. It has multiple effects on the vascular system. Inhibits relaxation induced by acetylcholine and induces an increase in arterial blood pressure. Abolishes lecithinized superoxide dismutase induced vasodilation when used to pretreat aortic ring preparations of mice. Induces leukocyte adhesion and increases microvascular fluid and protein fluxes and permeability. It has also been used in many studies of learning and memory.
N7251 4-Nitrocatechol sulfate dipotassium salt crystalline    
N7778 7-Nitroindazole ≥98% Selective inhibitor of nitric oxide synthase from mouse brain.
human ... NOS1(4842), NOS2(4843), NOS2B(201288), NOS2C(645740), NOS3(4846)
rat ... Nos1(24598)
N5879 O-(4-Nitrophenylphosphoryl)choline    
N4779   5-Nitro-2-(3-phenylpropylamino)benzoic acid ≥98% Potent chloride channel blocker.
N5636 3-Nitropropionic acid ≥97% Administering 3-nitropropionic acid (3-NP) to the inner ear can stimulate sensorineural hearing loss. It serves as an irreversible inhibitor of mitochondrial complex II.
Excitotoxin shown to cause brain lesions similar to those of Huntington′s disease.
Q109 6-Nitroquipazine maleate salt solid Potent and selective serotonin transport blocker.
human ... HTR1A(3350), HTR1B(3351), HTR1D(3352), HTR1E(3354), HTR1F(3355), HTR2A(3356), HTR2B(3357), HTR2C(3358), HTR3A(3359), HTR3B(9177), HTR3C(170572), HTR3D(200909), HTR3E(285242), HTR4(3360), HTR5A(3361), HTR5B(645694), HTR6(3362), HTR7(3363)
N0756 N-Nitrosodiethylamine liquid N-Nitrosodiethylamine (NDMA) is carcinogenic in all animal species tested. The main target organs are the nasal cavity, trachea, lung, esophagus and liver. NDMA is acted upon by the cytochrome P450 system resulting in the formation of carcinogenic methyldiazonium ion. However microbes like Pseudomonas metabolize NDMA into N-nitromethylamine (NTMA) and formaldehyde.
SML2960   Nizatidine ≥98% (HPLC) New Nizatidine is a potent and selective antagonist of histamine H2 receptors used for treatment of stomach and intestine ulcers. Also, it was recommended as a component of combination therapy for cancer treatment. New data indicate that it can be repurposed to treat subtypes of clear cell renal cell carcinoma (ccRCC) in patients expressing certain isoforms of the pyruvate kinase muscle type. Additionally, nizatidine increases utrophin A levels in in C2C12 myoblasts (relevant to Duchenne muscular dystrophy).
SML0944   NK-252 ≥98% (HPLC) NK-252 is a very potent, specific activator of the transcription factor Nrf2, which activates antioxidant-associated genes. NK-252 induces expression of an antioxidant response element promoter driven reporter gene, and protects Huh-7 liver cells against H202 induced cytotoxicity.
N3290 NKH 477 ≥98% (HPLC), powder NKH 477 is a potent, orally active adenylyl cyclase activator. It is a water soluble derivative of forskolin, and dose dependentyl increases cAMP and blocks potassium-induced contraction concetrations in smooth muscle strips (IC50 = 80 nM). NKH 477 causes relaxation of histamine treated guinea pig smooth muscle (IC50 = 32 nM).
N2165 NKY80 ≥98% (HPLC) NKY80 is a selective adenylyl cyclase-V inhibitor with greater than 200-fold selectivity for type V over the type II isoform.
SML2324 NLX-112 hydrochloride ≥98% (HPLC) NLX-112 (also known as befiradol or F13640) is a highly selective 5-HT1A receptor full agonist with >1000-fold selectivity compared to other types of receptors. It has been investigated for the treatment of Parkinson′s disease patients who exhibit L-DOPA-induced dyskinesia
N4912   NMA-Gly-Cys-Gly-Val-Leu-Leu-Lys(dnp)-Arg-Arg-NH2 trifluoroacetate salt ≥95% (HPLC), solid Notch 1 Peptide, fluorogenic
SML1538   NMDI14 ≥97% (HPLC) NMDI14 is a potent nonsense-mediated RNA decay (NMD) inhibitor. NMDI14 targets a pocket in the SMG7 protein and disrupts SMG7–UPF1 interactions. NMDI14 restores of full-length p53 protein activity in in cells with premature termination codons (PTC) mutated p53.
SML1128 NMS-873 ≥98% (HPLC) NMS-873 is a selective allosteric non–ATP-competitive inhibitor of the AAA ATPase family member valosine containing protein (VCP), also known as p97 (VCP/p97), an integral component of the ubiquitin fusion degradation (UFD) pathway. VCP/p97 plays a role in degradation of misfolded proteins, Golgi membrane reassembly, membrane transport, myofibril assembly, autophagosome maturation, and cell division, and is overexpressed in many tumor types. NMS-873 is the most potent and specific VCP inhibitor described to date. NMS-873 has an IC50 of 30 nM for VCP/p97 compared to IC50 >10 μM against all of the AAA ATPases, HSP90 or the 53 kinases analyzed. NMS-873 inhibited proliferation of HCT116 cancer cell line cells with an IC50 value of 400 nM.
SML0553 NN414 ≥98% (HPLC) NN414 is a potent Kir6.2/SUR1 selective K-ATP channel opener. Activation of the pancreatic Kir6.2/SUR KATP channels inhibits insulin release to induce beta cell rest, reducing the workload of the beta cell which is thought may prove beneficial for patients with type 2 diabetes. A recent study found that NN414 also triggered burst-like discharges in substantia nigra dopamine neurons. These K-ATP channel enabled burst-like discharges are associated with novelty-dependent exploratory behavior and may also have relevance to Parkinson′s disease.
N0287 NNC 55-0396 hydrate ≥98% (HPLC) NNC-55-0396 is a T-type calcium channel antagonists. It is the structural analog of mibefradil. NNC-55-0396 has the ability to block cell proliferation and stimulate cell apoptosis in leukemia cell lines.
Selective T-type calcium channel inhibitor
N6414 NN-DNJ ≥98% (HPLC) NN-DNJ is a glucosidase inhibitor that acts as a pharmacologic chaperone. NN-DNJ also acts synergistically with proteostasis modulators such as celastrol and MG132 to stabilize mutant proteins in properly folded states. NN-DNJ stabilizes various proteins against misfolding, increasing proper trafficking from the endoplasmic reticulum. There is potential use in studying diseases marked by misfolded proteins and has shown antiviral activity.
SML0584 NNGH ≥98% (HPLC) NNGH is a potent and cell-permeable inhibitor of matrix metalloproteinase 3 (MMP-3,stromelysin 1, progelatinase). NNGH has been used to inhibit MMP-3 in a variety of studies. Inhibition of MMP-3 with NNGH significantly suppressed the expression of iNOS and pro-inflammatory cytokines and the activities of NF-KB, AP-1, and MAPK in LPS-stimulated microglia, suggesting a role for MMP-3 in neuroinflammation.
N1540 NO-1886 Lipoprotein lipase activator. Overexpression of lipoprotein lipase in transgenic rabbits leads to increased small dense LDL in plasma and promotes atherosclerosis. Long-term administration of NO-1886 protects against the development of experimental atherosclerosis in animals.
N142 NO-711 hydrochloride ≥98% (HPLC) NO-711 is a potent and selective GABA uptake inhibitor that crosses the blood-brain barrier.
human ... GABBR1(2550), GABBR2(9568), GABRA1(2554), GABRA2(2555), GABRA3(2556), GABRA4(2557), GABRA5(2558), GABRA6(2559), GABRB1(2560), GABRB2(2561), GABRB3(2562)
M1404 Nocodazole ≥99% (TLC), powder Nocodazole is an antimitotic agent that disrupts microtubules by binding to β−tubulin and preventing formation of one of the two interchain disulfide linkages, thus inhibiting microtubule dynamics, disruption of mitotic spindle function, and fragmentation of the Golgi complex. Nocodazole arrests the cell cycle at G2/M phase and also prevents phosphorylation of the T cell antigen receptor and inhibits its activity. Nocodazole stimulates the intrinsic GTPase activity of tubulin and activates the JNK/SAPK signaling pathway and induces apoptosis in several normal and tumor cell lines. Nocodazole has been shown to enhance CRISPR homology-directed repair (HDR) efficiency and increase Cas9-mediated editing frequencies.
human ... TUBB(203068)
SML0379 Nodinitib-1 ≥98% (HPLC) Nodinitib-1 (ML130) is a selectiove inhibitor of of the nucleotide oligomerization domain (NOD)-1 receptor, which is involved in innate immune response and has been associated with several inflammatory diseases. NOD1 and NOD2 recognize distinct structures derived from bacterial peptidoglycans and directly activate NF-?B pathway, which controls the production of proinflammatory molecules. Nodinitib-1 has 40:1 selectivity for NOD1 over NOD2.
SML0473   Noladin ether ≥98% (HPLC) Noladin ether (2-Arachidonyl glycerol ether) is a stable analog of the endogenous cannabanoid 2-Arachidonylglycerol (2-AG) with selectivity for CB1 receptors. Noladin ether is a CB1 agonist. The Ki values for CB1 vs CB2 receptors are 21.2 nM and 3 mM, respectively. Noladin ether induces sedation and has modest antinociceptive activity in vivo, and reduces inter ocular pressure after administration in the eye.
SML2909 Nolatrexed dihydrochloride ≥98% (HPLC) Nolatrexed dihydrochloride is a water-soluble lipophilic quinazoline folate analog that exhibits potent antineoplastic activity. Nolatrexed is a potent thymidylate synthase inhibitor that inhibits thymine synthesis followed by inhibition of DNA replication.
N1530 Nomifensine maleate salt Nomifensine maleate is a selective dopamine uptake inhibitor interacting with the dopamine transporter, at a site different from that of cocaine; antidepressant. Nomifensine serves as an antidepressant and is known to cause frequent hemolytic anemia. The aniline group in this compound results in blood and liver toxicities.
human ... DBH(1621), SLC6A2(6530), SLC6A3(6531), SLC6A4(6532)
C2137   Non-hydroxy fatty acid ceramide from bovine brain ≥99% Involved in the action of phospholipase C on sphingomyelin.
SML1255 Nonyloxytryptamine oxalate ≥98% (HPLC) Nonyloxytryptamine (5-nonyloxytryptamine) is a potent and selective 5-HT1B receptor agonist. Nonyloxytryptamine is a polysialic acid (PSA) mimick that triggers PSA-mediated functions. Nonyloxytryptamine enhances neurite outgrowth of cultured primary neurons, protects neurons from oxidative stress, enhanced Schwann cell proliferation, reduces migration of astrocytes and enhances myelination in vitro.
Nonyloxytryptamine is known to possess antiproliferative and cytotoxic effect. It has been studied for its use in the treatment of breast cancer.
SML1144 Noopept ≥98% (HPLC) Noopept is a nootropic and neuroprotective drug that normalizes the balance of the pro- and antioxidant systems. Noopept modulates a variety of physiological functions including cognition and anxiety. Noopept significantly weakens streptozotocin-Induced diabetes in rats.
N8784 Norcantharidin solid Norcantharidin is a potential antitumor agent. Norcantharidin helps to block SK-N-SH neuroblastoma cell growth by stimulating autophagy and apoptosis.
human ... PPP2R5A(5525)
N5023 Nordihydroguaiaretic acid ≥90% (HPLC), from Larrea divaricata (creosote bush) Lipoxygenase inhibitor; polyphenol-bearing o-dihydroxy (catechol) structure.
human ... ALOX15(246), PTGS1(5742), PTGS2(5743)
mouse ... Alox12(11684)
A7257 (−)-Norepinephrine ≥98%, crystalline Adrenergic neurotransmitter
human ... ADRA1A(148), ADRA1B(147), ADRA1D(146), ADRA2A(150), ADRA2B(151), ADRA2C(152), ADRB1(153), ADRB2(154), ADRB3(155)
rat ... Adra1a(29412), Adra1d(29413), Adra2a(25083), Adrb1(24925), Adrb2(24176), Drd1a(24316), Drd2(24318)
A0937 (±)-Norepinephrine (+)-bitartrate salt Adrenergic neurotransmitter
human ... ADRA1A(148), ADRA1B(147), ADRA1D(146), ADRA2A(150), ADRA2B(151), ADRA2C(152), ADRB1(153), ADRB2(154), ADRB3(155)
A9512 L-(−)-Norepinephrine (+)-bitartrate salt monohydrate ≥99%, solid Norepinephrine bitartrate plays an important role in in vivo and in vitro development of pathogenic and indigenous bacteria. It acts as a vasoconstrictor and adrenergic neurotransmitter.
N4128 19-Norethindrone ≥98%, powder 19-norethindrone is an oral contraceptive involved in the inhibition of cytosolic sulfotransferases (SULT).
human ... AR(367), PGR(5241)
rat ... Ar(24208)
N3288 (+)-Norfenfluramine hydrochloride ≥98% (HPLC), powder (+)-Norfenfluramine is the major hepatic metabolite of (+)-fenfluramine and is primarily responsible for the anorexic effect, as well as side effects; (+)-norfenfluramine causes vasoconstriction and a blood pressure increase in rats with normal blood; acts primarily on the cytoplasmic pool of serotonin; more potent than fenfluramine at inducing dopamine release.
SML0359 Norgestimate ≥97% (HPLC) Norgestimate is a synthetic progestin used in combination with estrogens as a contraceptive.
human ... PGR(5241)
N6252 Norharmane crystalline Inhibitor of indoleamine 2,3-dioxygenase (IDO).
human ... IKBKB(3551)
rat ... Gabra2(29706)
N7127 DL-Normetanephrine hydrochloride ≥98% Norepinephrine metabolite.
N3018 (±)-Nornicotine ≥98% (TLC), liquid Nicotinic acetylcholine receptor agonist; active metabolite of nicotine; tobacco alkaloid.
mouse ... Chrna1(11435), Chrna7(11441)
rat ... Chrna4(25590)
N7252 19-Nortestosterone 19-Nortestosterone (nandrolone) is an anabolic steriod hormone that acts as an androgen receptor (AR) agonist.
human ... SERPINA6(866), SHBG(6462)
rat ... Ar(24208), Nr3c2(25672), Pgr(25154)
N7261 Nortriptyline hydrochloride ≥98% (TLC), powder Tricyclic antidepressant that is a more potent inhibitor of the norepinephrine transporter (Ki = 3.4 nM) than the serotonin transporter (Ki = 161 nM). 5-HT2 serotonin receptor antagonist.
human ... HTR2A(3356), HTR2B(3357), HTR2C(3358), SLC6A2(6530), SLC6A4(6532)
V108 (±)-Norverapamil hydrochloride ≥98% (HPLC) Norverapamil is an N-demethylated metabolite of verapamil. It has significantly less calcium channel blocking ability and exhibit therapeutic activity.
N2040 2-NP ≥98% (HPLC) 2-NP is a STAT1 Enhancer
SML2736 NPBA ≥98% (HPLC) NPBA is a potent and selective agonist (activator) of potassium K2P channel TASK-3 (KCNK9).
N161 NPC-15437 dihydrochloride hydrate ≥97% (NMR), powder Selective protein kinase C inhibitor.
SML0507 NPC26 ≥98% (HPLC) NPC26 induces mitochondrial fragmentation and cell death in RAS expressing cells, similar to erastin. The effects of NPC26 are independent of ROS scavengers, which can block cell death induced by erastin.
SML0426 NPD4456 ≥98% (HPLC) NPD4456 is an HIV-1 Vpr inhibitor that directly binds to HIV-1 Vpr. NPD4456 inhibits Vpr-dependent viral infection of human macrophages. Vipirinin analogue.
SML2637 NPD8733 ≥98% (HPLC) NPD8733 is an inhibitor of cancer cell-enhanced fibroblast migration. NPD8733 binds to valosin-containing protein (VCP)/p97.
SML1057   NPP ≥98% (HPLC) NPP is a ROS promoter selective for cancer tissue. NPP is a potent and preferential tumor cell death inducer that causes apoptosis in cancer cells by cytochrome P450 catalyzed ROS formation.
SML0362 NPS2143 hydrochloride ≥98% (HPLC) NPS2143 is a phenylalkylamine calcilytic compound, and might be useful in treating autosomal dominant hypocalcemia. It serves as a blocking agent for hERG (human ether-a-go-go-related gene ) channel, CYP2D6 (cytochrome P450 2D6 ) and monoamine transporters.
NPS2143 is a selective calcium-sensing receptor (CaR) antagonist. The compound blocks increases in cytoplasmic calcium concentrations with an IC50 of 43 nM, and stimulates parathyroid hormone (PTH) secretion from bovine parathyroid cells over a wide range of extracellular calcuim concentrations.
SML1337 NQ301 ≥98% (HPLC) NQ301 is an antithrombotic agent. Recent study shows that NQ301 (Compound 211) is a highly potent, selective, non-competitive allosteric inhibitor of CD45 that selectively inhibits dephosphorylation of substrate Lck pY-505 versus Lck pY-393. NQ301 prevents T cell receptor-mediated activation of Lck, Zap-70 and MAPK, and IL-2 production in primary T-cells. NQ301 exhibits immunosuppressive activity in mice.
SML0185 NQDI-1 ≥98% (HPLC) NQDI-1 inhibits the activation of caspase-3 and prevents cell death by apoptosis. It is neuroprotective and prevents the ROS-induced apoptosis of the neurons.
NQDI-1 is an inhibitor of apoptosis signal-regulating kinase (ASK1), Ki = 500 nM. NQDI-1 shows little or no inhibitory activity against Aurora A or ROCK kinases, or several receptor tyrosine kinases.
SML1104 NQTrp ≥98% (HPLC) NQTrp is a potent inhibitor of amyloid aggregation (AD). NQTrp completely inhibits Ab oligomerization and fibrillization, and the cytotoxic effect of Ab oligomers in cultured neuronal cell line.
SML2126 NS1209 ≥98% (HPLC) NS1209 (SPD 502) is a potent, selective, water-soluble and in vivo long-lasting AMPA antagonist. NS1209 exhibits neuroprotective activity in animal models of stroke, neuropathic pain and epilepsy.
N0663 NS1643 ≥98% (HPLC), solid The new diphenylurea compound 1,3-bis-(2-hydroxy-5-trifluoromethyl-phenyl)-urea (NS1643) was tested in hERG channel. In Xenopus laevis oocytes, NS1643 increased both steady-state and tail current at all voltages tested. The EC50 value for hERG channel activation was 10.5 μM. The effect could be reverted by application of the specific hERG channel inhibitor 4′-[[1-[2-(6-methyl-2-pyridyl)ethyl]-4-piperidinyl]carbonyl]-methanesulfonanilide (E-4031) at 100 nM. Application of NS1643 also resulted in a prolonged postrepolarization refractory time. hERG channel activation by small molecules such as NS1643 increases the repolarization reserve and presents a new antiarrhythmic approach.
N211 NS 2028 solid Specific, soluble guanylyl cyclase inhibitor.
human ... GUCY1A2(2977), GUCY1A3(2982), GUCY1B2(2974), GUCY1B3(2983)
N8161 NS309 ≥98% (HPLC), solid NS309 is a Ca2+-activated IK/SK potassium channel activator.
SML2843 NS3623 ≥98% (HPLC) NS3623 is a potent and selective activator of KV11.1 (hERG) and KV4.3 channels. It activates the IKr and Ito currents and exhibits antiarrhythmic activity. NS3623 may also act as a partial blocker of KV11.1 channels.
N7787 NS3694 ≥98%, powder NS3694 is an Inhibitor of apoptosome formation.
human ... GRIK1(2897)
SML1964   NS3728 ≥98% (HPLC) NS3728 (Endovion) is a di-aryl-urea-based reversible anion channel blocker that is shown to inhibit Ca(2+)-independent Cl- conductance by volume-regulated anion channel (VRAC or VSOAC; IC50 = 400 nM) as well as Ca2+-activated Cl- ccurrent (CaCC) by anoctamin (ANO) in an apparently voltage-dependent manner (IC50 against ANO1 = 2.1 and 0.7 μM at -95 and +50 mV, respectively). NS3728 is reported to be 5.5-times more potent than Tamoxifen against VRAC (IC50 = 0.4 vs. 2.2 μM).
N1162 NS3763 ≥98% (HPLC), solid First non-competitive antagonist of GluK5 receptor.
SML2173 NS3861 ≥98% (HPLC) NS3861 is a neuronal nicotinic receptor agonist that selectively activates α3 containing nAChRs and it displays higher efficacy at the α3β2 receptor compared with the α3β4 receptor. NS3861 does not activate α4 containing receptors. NS3861 was reported to reverse chronic opioid-induced constipation in vivo.
N194 NS-398 ≥98% (HPLC), solid Selective cyclooxygenase-2 (COX-2) inhibitor.
human ... ALOX5(240), CYP19A1(1588), PTGS1(5742), PTGS2(5743)
mouse ... Ptgs2(19225)
N2540 NS5806 ≥98% (HPLC) NS5806 increases peak current amplitude of the potassium channel Kv4.3 (EC50 = 5.3 uM). NS5806 also slows Kv4.3 and Kv4.2 current dacay in channel complexes containing KChIP2. In ventricular cardiomycytes, NS5806 increases transient outward current and reproduces the electrocardiographic profile of Brugada syndrome.
SML0745   NS6180 ≥98% (HPLC) NS6180 is a novel inhibitor of the intermediate-conductance Ca2+-activated K+ channel (KCa3.1) The IC50 of NS6180 against cloned human KCa3.1 is 9 nM. The compound blocks proliferation and production of IL-2 and IFNγ with sub-micromolar potencies in either ConA or PMA/ionomycin challenged rat splenocytes.
N2538 NS8593 hydrochloride ≥98% (HPLC), powder The compound (R)-N-(benzimidazol-2-yl)-1,2,3,4-tetrahydro-1-naphtylamine (NS8593) reversibly inhibited recombinant SK3-mediated currents (human and rat SK3) with potencies around 100 nM. NS8593 did not inhibit 125I-apamin binding. NS8593 decreased the calcium sensitivity by shifting the activation curve for Ca2+ to the right, only slightly affecting the maximal Ca2+-activated SK current. NS8593 inhibited all the SK1-3 subtypes Ca2+-dependently (Kd = 0.42, 0.60, and 0.73 μM, respectively, at 0.5 μM Ca2+. NS8593 did not affect the calcium-activated potassium channels of intermediate and large conductance (hIK and hBK channels, respectively). NS8593-mediated inhibition was prevented in the presence of a high concentration of the positive modulator NS309.
SML2537 NSAH ≥98% (HPLC) NSAH is a cell penetrant, potent and selective nonnucleoside reversible inhibitor of large subunit (hRRM1) of hRR (human ribonucleotide reductase). NSAH binds to catalytic site of hRRM1. It inhibits hRR in cells. NSAH exhibit potent cytotoxicity toward cancer cells, while demonstrated very moderate toxicity against normal blood progenitor cells.
SML0781   NSC109555 ≥98% (HPLC) NSC109555 is a selective inhibitor of Chk2 (IC50 = 310 nM). The compound is reversible and competitive for ATP, and displays little or no activity against other related kinases, including Chk1, at concentrations up to 10 μM.
SML0922   NSC130813 ≥98% (HPLC) NSC130813 blocks protein-protein interactions between XPF and ERCC1, two proteins involved in nucleotide excision repair (NER). The compound, NSC130813, blocks repair of DNA damage induced by platinum-based ctyotoxic drugs and DNA alkylating agents. NSC130813 synergistically potentiates cell death in cancer cell lines treated with cisplatin or mitomycin C.
SML2570 NSC 146109 hydrochloride ≥98% (HPLC) NSC146109 is a potent activator of p53 that selectively inhibits growth of transformed cells without genotoxicity. NSC146109 activates p53 by inhibition of MDMX expression.
SML2986 NSC 15520 ≥98% (HPLC) New NSC15520 is an inhibitor of the N-terminal protein interaction domain of Replication Protein A (RPA), the major single-stranded DNA binding protein in eukaryotes, which is required for DNA replication, DNA repair, DNA recombination, and DNA damage response signaling. It has been shown to block the association of RPA to p53 and RAD9. In pluripotent stem cells, NSC 15520 increased targeted nucleotide substitutions in CRISPER reactions using Cas9n and Cpf1. It has been used along with a group of other small molecules to achieve a 2.8 to 7.2-fold increase in precision gene editing with Cas9.
SML1580   NSC156529 ≥98% (HPLC) NSC156529 is a potent inhibitor of Akt/PKB pathway that decreases the proliferation of human cancer cells in vitro, and inhibits tumor growth in a prostate tumor xenograft model. NSC156529 inhibits interaction of PDPK1 and AKT1 by direct binding to PDPK1. NSC156529 increases the differentiation status of cancer cells.
SML0952   NSC23766 trihydrochloride ≥97% (HPLC) NSC23766 is an inhibitor of Rac1, a Rho-family GTPase. The compound blocks activation by the guanine nucleotide exchange factors Trio and Tiam1, but does not affect interactions with RhoA or Cdc42. NSC23766 blocks ADP-mediated platelet aggregation. Inhibition of Rac1 by NSC23766 restores sensitivity to trastuzumab by restoring down-regulation of ErbB2.
SML0372 NSC23925 ≥98% (HPLC) NSC23925 is a specific Pgp1 inhibitor. It reverses MDR1 (Pgp1) but does not inhibit MRP or BCRP-mediated MDR. NSC23925 itself is not a substrate of Pgp1 but stimulates ATPase activity of Pgp, directly inhibiting the function of Pgp1 in a dose-dependent manner without altering the total expression level of Pgp1.
N9413 NSC 295642 ≥98% (HPLC), solid NSC 295642 is a potent inhibitor of cell migration. Cell migration is a basic biological process involved in a range of normal and pathological events, including wound healing, embryonic and tissue development, immune function and inflammation, angiogenesis and tumor metastasis. Therefore, cell migration can be adapted as an important biological tool to monitor several physiological processes as well as development of cancer. Accordingly, a potent inhibitor of cell migration, such as NSC 295642 can elucidate the intrinsic molecular mechanism of many biochemical events.
N8914 NSC308848 ≥98% (HPLC), powder NSC308848 is a small molecular transcription factor inhibitor.
SML0069 NSC 33994 ≥98% (HPLC) NSC 33994 is a potent and specific Jak2 inhibitor that inhibits a notorious mutation, Jak2-V617F, found in large number of myeloproliferative neoplasms.
Potent and specific Jak2 inhibitor effective against Jak2-V617F mutation
N3414 NSC348884 hydrate NSC 348884 is a putative inhibitor of nucleophosmin (NPM). NSC 348884 inhibits NMP oligomer formation, up-regulates p53 and induces apoptosis.
SML0973 NSC 37249 dihydrochloride ≥98% (HPLC) NSC 37249 is a potent inhibitor of adenovirus proteinase (IC50 = 0.14 μM).
SML0518   NSC405020 ≥98% (HPLC) NSC405020 is a PEX inhibitor targeting the PEX domain of MT1-MMP that repressed tumor growth and caused a fibrotic DPEX-like tumor phenotype in vivo. NSC405020 does not inhibit the catalytic activity of MMP-2.
N0915 NSC43067 ≥98% (HPLC) NSC43067 is a Cyclin-dependent kinase (Cdk) inhibitor which binds to a novel conserved site on Cdk, presumably the p27 binding pocket. The binding apparently directly induces Cdk1, Cdk2, and Cdk4 protein aggregation. Cdks 1, 2, 4, and 6 are the key Cdks that regulate the cell cycle, and are a target for a cancer treatment. NSC43067 arrests the cell cycle at the G0/G1 phase at lower concentrations and at the G2/M cell cycle phase at higher concentrations. The action appears to be reversible.
SML2544 NSC49652 ≥98% (HPLC) NSC49652 is a orally active, potent and selective inhibitor of death receptor p75NTR (p75 neurotrophin receptor) that targets the interfaces between transmembrane domains (TMDs). NSC49652 induces profound conformational changes and triggers p75NTR dependent cancer cell death. It inhibits the growth of cancer in melanoma mouse model.
SML1863 NSC57969 ≥98% (HPLC) NSC57969 is a MDR-selective compound that exhibits a robust Pgp-dependent toxic activity across diverse cancer cell lines. NSC57969 shows profound toxicity against doxorubicin resistant Brca1-/-;p53-/- spontaneous mouse mammary carcinoma cells. NSC57969 eradicates P-glycoprotein expression in doxorubicin resistant brca1-/-;p53-/- spontaneous mouse mammary carcinoma, and MES-SA/Dx5 cells. However treatment of normal cells (hCMEC/D3 cells) with NSC57969 does not induce loss of Pgp.
SML1601 NSC59984 ≥98% (HPLC) NSC59984 targets various mutant p53 to restore wild-type p53 pathway via the activation of p73 in cancer cells. NSC59984 depletes a gain of function (GOF p53 mutants. NSC59984 is not cytotoxic against normal cells.
SML2293 NSC61610 ≥98% (HPLC) NSC61610 is an orally available and potent lanthionine synthetase C-like 2 (LANCL2) ligand that induces IL-10-mediated anti-inflammatory responses that ameliorate disease activity and decrease inflammatory lesions in the gut. Also NSC61610 modulates immune response to influenza A H1N1pdm virus infection in mice.
SML1005   NSC 617145 ≥98% (HPLC) NSC 617145 has an IC50 value of 230nM.
NSC 617145 is a potent and cell-permeable inhibitor of Werner syndrome helicase (WRN) that causes accumulation of double-strand breaks (DSB) and chromosomal abnormalities in cancer cells.
SML0270 NSC 632839 ≥98% (HPLC) NSC 632839 is an ubiquitin isopeptidases inhibitor targets the ubiquitinproteasome system (UPS).
N7537 NSC 663284 ≥98% (HPLC), solid NSC 663284 is a quinolinediones, which is involved in the inhibition of cell cycle progression at both G1 and G2/M phase. It is also involved in inhibiting the dephosphorylation and activation of cyclin-dependent kinases (Cdks) in vitro and in vivo. NSC 663284 stops the proliferation of various tumor cell lines.
Potent, irreversible, cell permeable and mixed competitive CDC25 phosphatase family inhibitor
human ... CDC25B(994), DUSP3(1845), PTPN1(5770)
SML0046 NSC 668036 hydrate ≥98% (HPLC) NSC 668036 binds to the PDZ domain of the Wnt-pathway signaling molecule Disheveled (Dvl), blocking the binding and activation of Dvl by Frizzled. In Xenopus embryos, NSC 668036 inhibited Wnt3A-induced expression of the target gene Siamois and formation of secondary axes.
SML1320 NSC687852 ≥98% (HPLC) NSC687852 is a cell-permeable, potent, reversible and selective inhibitor of 19S regulatory-particle-associated deubiquitinases (DUBs) UCHL5 and USP14, with no effect on UCH-L1, UCH-L3, USP2, USP7, USP8 and BAP1 and on the proteasomal proteolytic activities. NSC687852 induces cell-cycle arrest and apoptosis in several colon cancers and in CNS cells, and suppresses tumor growth in various mouse models.
SML0618   NSC697923 ≥98% (HPLC) NSC697923 is a cell-permeable and selective inhibitor of the ubiquitin-conjugating (E2) enzyme Ubc13-Uev1A that blocks the formation of the Ubc13 - ubiquitin thioester conjugate, and suppresses constitutive NF-kB activity in ABC-DLBCL cells. Also, NSC697923 inhibits the proliferation and survival of ABC-DLBCL and GCB-DLBCL cancer cells.
N8164 NSC727447 ≥98% (HPLC) NSC727447 is an inhibitor of ribonuclease H (Rnase H) of HIV-1 and HIV-2. NSC727447 has little activity against E. coli RNase H, but great selectivity over human Rnase H.
SML1897 NSC73306 ≥98% (HPLC) NSC73306, a thiosemicarbazone, is a cell penetrant, cytotoxic agent that exhibits greater toxicity against cells expressing functional P-gp (P-glycoprotein) than against other cells. Irrespective of variations in cell line background, NSC73306 consistently demonstrated a Pgp-potentiated MDR-selective toxicity. It appears that NSC73306 is transported into the cell by copper transporter 1 (CTR1, SLC31A1). It is not P-gp inhibitor.